Catherine Callaghan Coombs

机构：University of California, Irvine, University of California, Irvine Medical Center · ORCID：0000-0003-4656-7304

发表论文 227 篇 · 总被引 6231 次 · h-index 32

代表论文

• Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321) (2025 · Journal of Clinical Oncology · 被引 41)
• Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL (2024 · Blood Advances · 被引 25)
• Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2025 · Journal of Clinical Oncology · 被引 20)
• BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2024 · Blood · 被引 20)
• Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study (2025 · Blood Advances · 被引 5)
• Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor (2025 · Blood · 被引 2)